[go: up one dir, main page]

MX2008001865A - Albumin fusion proteins. - Google Patents

Albumin fusion proteins.

Info

Publication number
MX2008001865A
MX2008001865A MX2008001865A MX2008001865A MX2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A MX 2008001865 A MX2008001865 A MX 2008001865A
Authority
MX
Mexico
Prior art keywords
fusion proteins
albumin fusion
nucleic acids
vectors
host cells
Prior art date
Application number
MX2008001865A
Other languages
Spanish (es)
Inventor
Adam Bell
Yanggu Shi
David Lafleur
Craig Rosen
Paul Moore
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of MX2008001865A publication Critical patent/MX2008001865A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
MX2008001865A 2005-08-12 2006-07-31 Albumin fusion proteins. MX2008001865A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
MX2008001865A true MX2008001865A (en) 2008-04-15

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008001865A MX2008001865A (en) 2005-08-12 2006-07-31 Albumin fusion proteins.

Country Status (13)

Country Link
EP (1) EP1924596A4 (en)
JP (1) JP2009504157A (en)
KR (1) KR20080071119A (en)
AU (1) AU2006280312A1 (en)
BR (1) BRPI0614761A2 (en)
CA (1) CA2618476A1 (en)
EC (1) ECSP088262A (en)
IL (1) IL189246A0 (en)
MA (1) MA29836B1 (en)
MX (1) MX2008001865A (en)
NO (1) NO20081233L (en)
TN (1) TNSN08064A1 (en)
WO (1) WO2007021494A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
SI1729795T1 (en) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc Albumin fusion proteins
AU2007294805A1 (en) * 2006-09-14 2008-03-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2915168C (en) 2007-01-30 2017-05-23 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
BRPI0915093A2 (en) 2008-06-13 2015-10-27 Proyecto Biomedicina Cima Sl conjugates for the administration of biologically active compounds
UA103221C2 (en) * 2009-01-16 2013-09-25 Тева Фармасьютікал Індастріз Лтд. Stable formulation of recombinant human albumin-human granulocyte colony stimulating factor
KR101722961B1 (en) 2009-02-11 2017-04-04 알부메딕스 에이/에스 Albumin variants and conjugates
KR20100100254A (en) * 2009-03-05 2010-09-15 (주)바이오큐어팜 Composition for preventing or treating cancer comprising human serum albumin-timp-2 fusion protein and anti-cancer agent
BR112012004094A2 (en) 2009-08-24 2016-03-08 Amunix Operating Inc coagulation factor vii compositions and methods for making and using them
MX2012004793A (en) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Albumin variants.
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
JP6200806B2 (en) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド Bispecific fusion protein
CN107261119A (en) * 2011-02-28 2017-10-20 独立行政法人国立循环器病研究中心 Malignant tumor of bonal metastasis suppression medicine
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (en) 2011-10-21 2014-10-31 Abbvie Inc METHODS FOR THE TREATMENT OF HCV COMPREHENDING AT LEAST TWO ANTIVIRAL AGENTS OF DIRECT ACTIVITY, RIBAVIRIN, BUT NOT INTERFERED.
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EA035323B1 (en) 2012-01-12 2020-05-28 Биовератив Терапьютикс Инк. CHEMICAL FACTOR VIII POLYPEPTIDES AND THEIR APPLICATION
LT2822577T (en) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
HRP20221531T1 (en) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CN103525695B (en) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 Portable kidney function detecting system
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
KR20150082422A (en) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 Albumin variants
LT2956477T (en) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimized factor viii gene
CN105007722A (en) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 Pharmacokinetic animal model
EA037906B1 (en) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Factor ix polypeptide formulations
WO2014210558A1 (en) 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
DK3091997T5 (en) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
MX2018001497A (en) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
US10040840B2 (en) 2015-10-02 2018-08-07 Silver Creek Pharmaceuticals, Inc. Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
CN105254766B (en) * 2015-10-26 2018-10-16 中国航天员科研训练中心 Application of the Mecano growth factor MGF E domain peptides in regulation and control memory related gene and miRNA expression
PL3411478T3 (en) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Optimized factor VIII genes
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2020500306A (en) 2016-11-04 2020-01-09 オーフス ウニベルシテット Identification and treatment of tumors characterized by neonatal Fc receptor overexpression
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
BR112019011198A2 (en) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc methods of inducing immune tolerance to coagulation factors
MA47163A (en) 2016-12-16 2019-11-06 Biogen Ma Inc PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
EA201991768A1 (en) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. FUSIONED PROTEINS BASED ON FACTOR IX AND METHODS OF PRODUCING THEM AND WAYS OF APPLICATION
WO2018193033A1 (en) * 2017-04-20 2018-10-25 Novo Nordisk A/S Methods of purification of albumin fusion proteins
JP7374883B2 (en) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド Nucleic acid molecules and their uses
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
RS66972B1 (en) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Methods of treating hemophilia a
KR20210027426A (en) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 FGF21 formulation
CN119955796A (en) 2018-08-09 2025-05-09 比奥维拉迪维治疗股份有限公司 Nucleic acid molecules and their use in non-viral gene therapy
BR112021010047A2 (en) 2018-12-06 2021-08-24 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
CN115279896A (en) 2019-09-30 2022-11-01 比奥维拉迪维治疗股份有限公司 Lentiviral vector formulations
MX2023000156A (en) 2020-06-24 2023-02-16 Bioverativ Therapeutics Inc METHODS FOR THE ELIMINATION OF FREE FACTOR VIII FROM PREPARATIONS OF LENTIVIRAL VECTORS MODIFIED TO EXPRESS SAID PROTEIN.
WO2022030580A1 (en) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 Novel long-acting adrenomedullin derivative, method for producing same and pharmaceutical use thereof
US12487299B2 (en) 2022-06-20 2025-12-02 Shanghai United Imaging Healthcare Co., Ltd. Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices
JP2024056667A (en) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 Fusion protein of serum albumin and a biologically active protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
SI1729795T1 (en) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albumin fusion proteins
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
EP1924596A2 (en) 2008-05-28
IL189246A0 (en) 2008-08-07
ECSP088262A (en) 2008-05-30
NO20081233L (en) 2008-05-09
TNSN08064A1 (en) 2009-07-14
AU2006280312A1 (en) 2007-02-22
KR20080071119A (en) 2008-08-01
JP2009504157A (en) 2009-02-05
WO2007021494A2 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
MA29836B1 (en) 2008-10-03
BRPI0614761A2 (en) 2009-05-19
WO2007021494A3 (en) 2007-07-26
CA2618476A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (en) Albumin fusion proteins.
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2003060071A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
WO2003030821A3 (en) Albumin fusion proteins
ES2353814T3 (en) RECOMBINANT N-GLYCOSILATED PROTEINS OF PROCEDURAL CELLS.
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
EA201690946A1 (en) FGF21 MUTANTS AND THEIR APPLICATIONS
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
IN2012DN02981A (en)
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2006017355A3 (en) Improved aprotinin variants
TW200724679A (en) Treatment of disease using an improved regulated expression system
WO2002097110A3 (en) TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF
WO2006110367A3 (en) Methods and compositions for mycoplasma toxins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal